health ๐ FDA upgrades recall for superpotent thyroid tablets ๐จ
The FDA has upgraded the recall for Vitruvias Therapeutics' thyroid tablets to Class I due to superpotency risks. This affects approximately 3,655 units from lot number 504950, distributed nationwide between January 31 and September 30, 2025. Superpotent levels risk causing serious issues like rapid heart rate and hypertension in users. Elderly patients, pregnant women, and infants are identified as facing the greatest risk from these excess hormones. Patients with this batch should consult a healthcare provider immediately for next steps.